<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001639'>Hypertrophic cardiomyopathy</z:hpo> (HCM) is the most common inherited <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disorder</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> condition is defined by <z:hpo ids='HP_0001712'>left ventricular hypertrophy</z:hpo> and associated with functional limitation and premature <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In fact, many individuals are asymptomatic and the annual mortality in most modern series is 1% or less </plain></SENT>
<SENT sid="3" pm="."><plain>However, severe symptoms may develop at any age, and the risk of premature <z:hpo ids='HP_0011420'>death</z:hpo> from <z:hpo ids='HP_0011675'>arrhythmia</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, and progressive systolic impairment may complicate asymptomatic disease </plain></SENT>
<SENT sid="4" pm="."><plain>The clinical management of patients with HCM therefore encompasses (1) genetic counseling including discussion of indications for genetic testing and cascade family screening, (2) assessment of prognostic risk from <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, and <z:hpo ids='HP_0001635'>heart failure</z:hpo>, and (3) symptom management </plain></SENT>
<SENT sid="5" pm="."><plain>This article describes the interventional treatments in the management of severe symptoms associated with left ventricular outflow tract obstruction (<z:mp ids='MP_0010448'>LVOTO</z:mp>) </plain></SENT>
</text></document>